The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation

May combine two claims.

Inhibiting either ENTPD2 or ADK enhances immune checkpoint inhibitor activity, highlighting their importance in driving immunosuppression and their potential as therapeutic targets.

“Inhibition of either ENTPD2 or ADK enhanced the activity of immune checkpoint inhibitors, which highlights their significance in driving immunosuppression and their potential utility as therapeutic targets to enhance the efficacy of immune checkpoint inhibitors [90, 93].”

• cites [90] sourceSupported
• cites [93] sourceDisputed

  The Results section on Adk knockout reports the opposite direction for ADK: its loss promoted HCC growth and suppressed antitumor immune cells, rather than enhancing checkpoint-inhibitor activity. The Results section on extracellular adenosine sensing attributes improved anti–PD-1 activity to combined A2AR and A2BR receptor blockade, not inhibition of ADK or ENTPD2. No page numbers were provided in our copy. (LLM, conf=0.88)

  Checked by a reasoning model — may be wrong.

  Experimental — accuracy not yet measured

May combine two claims.

Solid tumors and metastases usually have hypoxic regions because tumor cell proliferation exceeds oxygen supply and tumor vasculature is irregular and dysfunctional.

“Solid tumors and their metastases typically manifest regions of hypoxia due to the rapid proliferation of tumor cells that frequently outstrips their oxygen supply, coupled with irregular and dysfunctional tumor vasculature [2].”

• cites [2] sourcePartly supported

  The Introduction states that hypoxia is present in 90% of solid tumors, and “Factors Contributing to Hypoxia in Cancer” links it to rapid tumor growth, oxygen demand exceeding supply, and abnormal, nonfunctional vessels (page numbers unavailable). The paper discusses hypoxia promoting metastasis, but the passages do not establish that metastases themselves typically contain hypoxic regions. (LLM, conf=0.84)

  Experimental — accuracy not yet measured

May combine two claims.

Under hypoxia, HIFs stabilize, enter the nucleus, heterodimerize with HIF-1β, bind HREs, and transcribe hundreds of hypoxia-adaptation genes.

“HIFs are stabilized under hypoxic conditions, where they translocate to the nucleus, heterodimerize with the constitutive HIF-1β subunit, and bind to the hypoxia-response element (HRE) within the regulatory elements of target genes to drive the transcription of hundreds of genes critical for the adaptation to hypoxia [9, 10].”

• cites [9] sourcePartly supported

  The section ‘HIF α Regulation by O2 Availability’ says hypoxia stabilizes HIF α and enables transcription of adaptive genes. The AUTHOR MANUSCRIPT passage says HIF α pairs with stable HIF1β and the resulting heterodimers bind HREs. Our copy does not establish the claimed nuclear translocation or the specific quantity of hundreds of genes. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites [10] sourceNot checked — no full text of the source

May combine two claims.

In some contexts where HIF-1α is lost or inactivated, such as renal cancer or medulloblastoma, HIF-2α becomes dominant in the hypoxia response, suggesting redundancy between isoforms.

“However, in certain contexts, such as in renal cancer or medulloblastoma where HIF-1α is lost or inactivated, HIF-2α acquires the dominant role in regulating the hypoxia response, suggesting a measure of redundancy between the two isoforms [5, 6].”

• cites [5] sourceSupported
• cites [6] sourcePartly supported

  The Introduction (page unavailable) says VHL-defective clear-cell renal carcinoma cells show a bias toward HIF-2α, and the Discussion (page unavailable) describes the 786-0 renal cancer line as expressing only HIF-2α. The Introduction also notes some overlapping effects between the isoforms. The paper does not address medulloblastoma or establish that HIF-2α takes over HIF-1α’s hypoxia-response role when HIF-1α is lost; it also emphasizes distinct effects of the isoforms. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

May combine two claims.

Renal cancers with FH/SDH mutations tend to preferentially express HIF-1α, unlike pVHL-deficient ccRCC tumors that constitutively express both isoforms or preferentially HIF-2α.

“Intriguingly, unlike pVHL-deficient ccRCC tumors that constitutively express both HIF isoforms or HIF-2α preferentially, renal cancers bearing FH/SDH mutations tend to preferentially express HIF-1α [20].”

• cites [20] sourcePartly supported

  The “HIF1a expression in HLRCC tumours” section reports very strong HIF-1α staining in three FH-associated renal cancers. The Discussion also reports HIF-1α accumulation in SDHB-associated paragangliomas, but not SDH-associated renal cancers. The paper does not establish preferential HIF-1α expression over HIF-2α or the claimed isoform pattern in pVHL-deficient clear-cell renal cancers. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

May combine two claims.

In normal development, HIF-1α dominates vasculogenesis while HIF-2α mainly contributes to later vessel remodeling and maturation, known as the HIF switch.

“In the normal developmental setting, HIF-1α plays a dominant role throughout vasculogenesis, whereas HIF-2α contributes primarily to vessel remodeling and maturation during the later stages of vasculogenesis (the HIF switch) [25].”

• cites [25] sourcePartly supported

  Section 3.1 links HIF-1α to embryonic vasculogenesis and describes HIF-2α as an enhancer of genes involved in vessel stabilization at the final stage of angiogenesis. It does not describe a developmental transition between them, call it a “HIF switch,” or place remodeling and maturation in the later stages of vasculogenesis. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

May combine two claims.

NF-κB regulates the hypoxic response by stimulating HIF-1α and HIF-1β transcription and by IKK-dependent stabilization of HIF-2α.

“Additionally, numerous studies have shown that NF-κB regulates the hypoxic response by stimulating the transcription of HIF-1α and HIF-1β, and by inducing IKK-dependent stabilization of HIF-2α [15–17].”

• cites [15] sourcePartly supported

  The paper’s main text (page unavailable) reports that IKKβ-responsive NF-κB activates HIF-1α transcription, supporting that part of the claim. It does not establish HIF-1β transcriptional stimulation; moreover, it reports that IKKβ was required for HIF-1α accumulation but not HIF-2α accumulation in the macrophages studied, contrary to the HIF-2α part. (LLM, conf=0.90)

  Experimental — accuracy not yet measured
• cites [16] sourcePartly supported

  The Introduction and Results report that NF-κB binds the HIF-1α promoter and increases HIF-1α mRNA, supporting the transcriptional part for HIF-1α. The Results instead say HIF-1β protein levels remained stable; they do not establish stimulation of its transcription. The IKK experiments concern hypoxia-induced HIF-1α levels, not IKK-dependent stabilization of HIF-2α (page numbers unavailable). (LLM, conf=0.90)

  Experimental — accuracy not yet measured
• cites [17] sourceSupported

May combine two claims.

RAS, PI-3K, ERK1/2 activation and pVHL loss cause hypoxia-independent HIF activation.

“Similarly, activation of RAS, PI-3K, or downstream ERK1/2 kinases, common in many cancer types, and loss of pVHL, frequently observed in clear cell renal cell carcinoma (ccRCC), result in hypoxia-independent activation of the HIFs [12–14].”

• cites [12]Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

• cites [13] sourcePartly supported

  The “pVHL: MASTER REGULATOR OF HIF” section states that loss of VHL expression stabilizes HIF-α and increases HIF activity irrespective of oxygen levels. The passages found do not support the additional claim that activation of RAS, PI-3K, or ERK1/2 causes hypoxia-independent HIF activation. (LLM, conf=0.87)

  Experimental — accuracy not yet measured
• cites [14] sourceNot checked — no full text of the source

May combine two claims.

HIF-1α is widely expressed in most tissues during hypoxia, while HIF-2α and HIF-3α have more restricted tissue-specific expression under hypoxia.

“HIF-1α is widely expressed in most tissue during hypoxia, whereas HIF-2α and HIF-3α show more restricted, tissue-specific expression under hypoxic conditions [4].”

• cites [4] sourceSupported

May combine two claims.

Elevated fumarate and succinate in renal cancers with SDH or FH mutations suppress PHD-mediated HIF-α hydroxylation and stabilize both HIF-1α and HIF-2α.

“Elevation of fumarate and succinate, such as in renal cancer subtypes bearing succinate dehydrogenase (SDH) or fumarate hydratase mutations, suppress HIF-α hydroxylation by the PHDs, resulting in the stabilization of both HIF-1α and HIF-2α [20].”

• cites [20] sourcePartly supported

  The Abstract and Discussion report fumarate and succinate accumulation in FH-deficient tumours, predominantly succinate accumulation in SDH-deficient tumours, and increased HIF-1α protein. They describe PHD inhibition as a plausible mechanism, not one demonstrated in these tumours. The paper does not establish stabilization of HIF-2α, and its SDH-mutant tumours are paragangliomas or phaeochromocytomas, not renal cancers. (LLM, conf=0.90)

  Experimental — accuracy not yet measured

May combine two claims.

GSK-3β phosphorylates HIF-1α, leading to pVHL-independent ubiquitination and degradation; HIF-2α phosphorylation has not been demonstrated.

“Conversely, the serine-threonine kinase GSK-3β can phosphorylate HIF-1α (phosphorylation of HIF-2α has not been demonstrated), leading to pVHL-independent ubiquitination and degradation [18].”

• cites [18] sourcePartly supported

  The Introduction (page not provided) describes GSK3β phosphorylation of HIF-1α and VHL-independent degradation; the Discussion (page not provided) reports ubiquitin-dependent degradation through FBW7. The paper does not address whether HIF-2α phosphorylation has been demonstrated, so it does not support that part of the sentence. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

May combine two claims.

HIF-2α is a central non-redundant regulator of erythropoiesis by inducing kidney EPO and promoting gut iron uptake, supporting erythroid progenitor maturation and proliferation.

“HIF-2α is a central non-redundant regulator of erythropoiesis by inducing erythropoietin (EPO) production by the kidney, and promoting iron uptake in the gut, which facilitates erythroid progenitor maturation and proliferation [21].”

• cites [21] sourcePartly supported

  The Abstract reports that intestinal HIF-2α is crucial for iron absorption in mice, and the Introduction describes HIF-2α as important in adult erythropoiesis and dominant in regulating EPO expression. The Results report increased kidney EPO after intestinal Hif2a deletion, but do not establish that HIF-2α induces kidney EPO. The copy also does not address erythroid progenitor maturation or proliferation. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

May combine two claims.

The angiogenic switch is a key event in transition from dormant hyperplasia to outgrowing vascularized tumor and is a hallmark of all solid tumor types.

“This ‘angiogenic switch’ is a key event that facilitates the transition from a dormant hyperplasia to an outgrowing vascularized tumor and is a hallmark of all solid tumor types [26].”

• cites [26] sourcePartly supported

  The Introduction describes angiogenesis as important for rapid tumor expansion, and the section on transgenic mouse models places the angiogenic switch between hyperplastic islets and solid tumors. But the paper calls it a potentially rate-limiting step for “many solid tumors,” not a demonstrated hallmark of all solid tumor types (section labeled Abstract in our copy; page unavailable). (LLM, conf=0.88)

  Experimental — accuracy not yet measured

May combine two claims.

HIF-2α, but not HIF-1α, is regulated by iron through an iron-responsive element in the 5' UTR of its transcript.

“Consistent with the central role of HIF-2α in the regulation of iron homeostasis, HIF-2α (but not HIF-1α) is also regulated by iron due to the presence of an RNA stem-loop element known as an iron-responsive element (IRE), in the 5’ untranslated region (UTR) of the HIF-2α transcript [22].”

• cites [22] sourceSupported

May combine two claims.

Although HIF-1α and HIF-2α can regulate similar target genes due to HRE conservation, glycolysis is primarily driven by HIF-1α rather than HIF-2α.

“Although HIF-1α and HIF-2α can regulate similar target genes due to the conservation of the HRE, multiple studies have shown that glycolysis is primarily driven by HIF-1α and not HIF-2α [37, 38].”

• cites [37] sourceNot checked — no full text of the source
• cites [38] sourceSupported

May combine two claims.

HIF-1α suppresses fatty acid oxidation by inhibiting medium-chain and long-chain acyl-CoA dehydrogenases in cancer cells, decreasing ROS and increasing proliferation, likely by reducing acetyl-CoA for the TCA cycle and mitochondrial respiration.

“Additionally, HIF-1α suppresses FAO through inhibition of medium-chain Acyl-CoA dehydrogenase and long-chain Acyl-CoA dehydrogenase in a panel of cancer cells, resulting in decreased ROS and increased proliferation, presumably by reducing the production of acetyl-CoA required for the TCA cycle, thus inhibiting mitochondrial respiration and concomitant ROS production [47].”

• cites [47] sourceSupported

May combine two claims.

Although glycolysis produces less ATP per glucose than OXPHOS, it maintains bioenergetic flux during oxygen deprivation and generates intermediates for biosynthetic pathways such as the pentose phosphate pathway and fatty acid or amino acid synthesis.

“While glycolysis is less efficient than oxidative phosphorylation (OXPHOS) in generating ATP per molecule of glucose, the switch to glycolysis enables maintained bioenergetic flux during oxygen deprivation, and generates glycolytic intermediates that can be diverted into biosynthetic processes such as the pentose phosphate pathway (PPP) for nucleotide biosynthesis or fatty acid and amino acid”

• cites [39] sourceSupported

May combine two claims.

Necrosis is common in many tumors and is associated with poor prognosis and increased metastasis risk.

“Necrosis is a common feature of many tumors and is associated with poor prognosis and increased risk of metastasis [28].”

• cites [28] sourceSupported

May combine two claims.

Combinations of multiple anti-angiogenic agents or anti-angiogenics with immunotherapy or chemotherapy show increased patient benefit and are widely used in many cancers.

“However, combinations of multiple anti-angiogenic agents with complementary pro-angiogenic targets, or of anti-angiogenics with other modalities such as immunotherapy, chemotherapy or other modalities, show increased patient benefit and are now widely used treatment options in many cancer types [35].”

• cites [35] sourcePartly supported

  The Introduction and the sections on combinations with chemotherapy and immune checkpoint inhibitors report potential or observed benefits across several cancers; the FDA-approved agents section identifies some combinations used in treatment. The paper does not establish that combinations of multiple anti-angiogenic agents are widely used treatment options, and its Conclusion and prospect cautions that toxicity can hinder clinical use and some combinations can reduce chemotherapy’s effects. No page numbers are available in our copy. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

May combine two claims.

HIF-2α-mediated antioxidant gene expression protects pancreatic β-cells from glucotoxicity in obesity, while in breast cancer this reduction in mitochondrial ROS is associated with increased chemoresistance and stem-like properties.

“HIF-2α mediated antioxidant gene expression protects pancreatic β-cells against glucotoxicity in the context of obesity, whereas in breast cancer, this HIF-2α mediated reduction in mitochondrial ROS is associated with increased chemoresistance and stem-like properties [50, 51].”

• cites [50] sourceNot checked — no full text of the source
• cites [51] sourceSupported

May combine two claims.

Many glucose-metabolism-targeting agents work in preclinical models, but selectivity problems, pathway redundancies, and bypass mechanisms may restrict their effectiveness as single agents in patients.

“While many of these have shown efficacy in pre-clinical models, challenges in achieving selectivity, combined with pathway redundancies and bypass mechanisms may limit their utility as single agents in the clinic [55].”

• cites [55] sourceSupported

May combine two claims.

HIF-1α activation induces less active ETC complex 1 and IV subunits, slowing electron transfer, while both HIF-1α and HIF-2α suppress mitochondrial biogenesis genes such as PGC1β and PINK1.

“In this regard, HIF-1α activation induces expression of less active ETC complex 1 and IV subunits, thus decelerating electron transfer through the ETC, whereas both HIF-1α and HIF-2α drive transcriptional programs that suppress genes involved in mitochondrial biogenesis such as PGC1β and PINK1 [42–44].”

• cites [42] sourceSupported
• cites [43] sourceNot checked — no full text of the source
• cites [44] sourcePartly supported

  In “Function of HIFs on mitochondrial dysfunction” (page not available), the paper says HIF-1 activates less-active ETC components associated with complexes I and IV, delaying electron transfer. It also describes reduced mitochondrial biogenesis through PGC-1β and PINK1-related pathways, but does not attribute those effects to both HIF-1α and HIF-2α. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

May combine two claims.

Mitochondria undergo metabolic alterations to reduce hypoxia-induced damage, including exchanging or modifying respiratory chain subunits, decreasing OXPHOS, lowering TCA intermediates, adapting ROS production, and reducing fatty acid oxidation.

“Thus, mitochondria undergo a variety of metabolic alterations to reduce hypoxia-induced damage, including by exchanging or modifying subunits of the respiratory chain, decreasing OXPHOS, lowering the TCA cycle intermediates, adapting ROS production, and reducing fatty acid oxidation (FAO) [41].”

• cites [41] sourcePartly supported

  Section 3.1 describes a hypoxia-related shift away from OXPHOS and inhibited expression of respiratory-chain subunits; section 3.2.1 describes inhibition of the TCA cycle. But the paper does not establish that TCA intermediates generally decrease: section 4.3 reports that succinate rises during hypoxia. Nor does the located discussion establish reduced fatty acid oxidation as part of this mitochondrial response; section 4.5 instead discusses increased FAO during a T-cell transition. Page numbers are unavailable in our copy. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

May combine two claims.

Tumor vasculature lacks pericyte and smooth muscle stabilization and lacks arterial or venous phenotype, causing leakage and poor blood flow and perfusion.

“Characteristics of tumor vasculature include lack of stabilization by pericytes and smooth muscle cells and a lack of an arterial or venous phenotype that leads to leakage, poor blood flow and perfusion (Figure 3) [25].”

• cites [25] sourceSupported

May combine two claims.

Because necrosis is associated with extreme hypoxia, HIF activation is commonly seen in peri-necrotic regions, and necrosis plus peri-necrotic HIF expression is significantly associated with poor prognosis in multiple tumor types.

“Since necrosis is associated with extreme hypoxia, activation of HIF is commonly observed in areas surrounding necrotic regions (peri-necrotic regions), and the presence of necrosis combined with peri-necrotic HIF expression is significantly associated with poor prognosis in multiple tumor types [30, 31].”

• cites [30] sourcePartly supported

  The Results (page unavailable) report HIF-1α staining around necrotic areas and a worse prognosis for patients with perinecrotic expression; the paper also describes this pattern as hypoxia-induced. Its prognostic analysis concerns breast cancer, however, and does not establish the claimed association across multiple tumor types. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [31] sourcePartly supported

  The Background describes necrosis as a marker of severe hypoxia, and the Results document perinecrotic HIF-1α expression. The Survival analysis results report that necrosis and perinecrotic HIF-1α expression each predicted poorer survival in patients with endometrioid endometrial carcinoma. The paper does not establish a prognostic effect for their combination across multiple tumor types. (LLM, conf=0.87)

  Experimental — accuracy not yet measured

May combine two claims.

Despite promising preclinical and early clinical results, glutamine-metabolism-targeting agents often have limited clinical effectiveness because of resistance from tumor heterogeneity and metabolic plasticity, and because of toxicity to normal tissue.

“However, despite promising results in preclinical and early clinical trials, their clinical effectiveness is often compromised by resistance mechanisms due to tumor heterogeneity and metabolic plasticity, as well as toxicity to normal tissue [63].”

• cites [63] sourceSupported

May combine two claims.

HIF-1α drives degradation of the E1 subunit of α-KG dehydrogenase, reducing α-KG oxidation in the TCA cycle, causing α-KG accumulation and facilitating its reductive carboxylation by IDH.

“HIF-1α also drives the degradation of the E1 subunit of α-KG dehydrogenase, which decreases the oxidation of α-KG in the TCA cycle, leading to accumulation of α-KG and facilitating its reductive carboxylation by IDH [61].”

• cites [61] sourcePartly supported

  The Results report increased α-ketoglutarate in hypoxic SF188 cells and propose that reduced oxidation through the TCA cycle could help explain increased reductive carboxylation. The Results and Discussion also link HIF1 activity to preferential IDH2-mediated reductive metabolism. Neither section reports that HIF-1α degrades the E1 subunit of α-ketoglutarate dehydrogenase or establishes that degradation as the cause of the metabolic shift. Page numbers are unavailable in our copy. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

May combine two claims.

HIF activates the transcriptional repressor MXI1, which inhibits ADK, leading to adenosine accumulation in hypoxic cancer cells.

“Additionally, HIF activates transcriptional repressor MXI1, which inhibits ADK, resulting in adenosine accumulation in hypoxic cancer cells [93].”

• cites [93] sourceSupported

May combine two claims.

Lack of HIF-1α or HIF-2α in TAMs decreases metastasis, cell proliferation, and expression of pro-inflammatory cytokines such as IL-6.

“Both HIF-1α or HIF-2α expression in TAMs have been associated with tumor progression and/or poor prognosis in multiple tumor types, whereas lack of HIF-1α or HIF-2α in TAMs decreases metastasis, cell proliferation, and expression of pro-inflammatory cytokines such as IL-6 [73–76].”

• cites [73] sourcePartly supported

  The Abstract Results associate TAM HIF-1α with increased metastasis, and the Results find inflammatory-response pathways enriched in HIF1A-positive macrophages. The paper does not show that loss of either HIF isoform in TAMs decreases metastasis, cell proliferation, or IL-6 expression; the Discussion also says macrophage-specific HIF-2α was not detected in the kidney tumors examined. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [74] sourcePartly supported

  The Hypoxia section links HIF activation to tumor progression and describes HIF-related conditions that promote proliferation and metastasis. The IL-6 section links TAM-secreted IL-6 to metastasis. Neither section reports that loss of HIF-1α or HIF-2α in TAMs decreases metastasis, proliferation, or IL-6 expression; no page numbers are available in our copy. (LLM, conf=0.82)

  Experimental — accuracy not yet measured
• cites [75] sourcePartly supported

  In the section on the syngeneic mouse mammary carcinoma model (page not available), HIF knockdown in breast cancer cells reduced metastasis; HIF-1α knockdown also reduced primary tumor growth. The knockdown was not in TAMs, and the cited passages do not establish reduced cell proliferation or IL-6 expression. (LLM, conf=0.87)

  Experimental — accuracy not yet measured
• cites [76] sourcePartly supported

  The tumor-progression section reports reduced tumor-cell mitosis and compromised progression after myeloid HIF-2α deletion. The cytokine section reports reduced IL-6 secretion from activated HIF-2α-deficient macrophages in vitro, but IL-6 reduction in the tumors is proposed as a possible explanation, not established. The paper does not report reduced metastasis or test HIF-1α deletion in these tumor models; it proposes the latter as future work. Page numbers are unavailable in our copy. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

May combine two claims.

HIF-1α activation induces GLS, which promotes the conversion of glutamine to glutamate.

“Additionally, HIF-1α activation promotes the induction of GLS, which promotes the conversion of glutamine to the metabolic intermediate, glutamate [60].”

• cites [60] sourcePartly supported

  The Introduction (page unavailable) says glutaminase participates in the conversion of glutamine toward α-ketoglutarate via glutamate. It does not say HIF-1α induces GLS. The Results section (page unavailable) instead identifies reduced α-ketoglutarate dehydrogenase activity as the effect of HIF stabilization. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

May combine two claims.

HIFs transcriptionally activate ENT4, which pumps adenosine into the interstitial space, elevating extracellular adenosine levels associated with immunosuppressive effects.

“The HIFs also transcriptionally activate ENT4, which pumps adenosine into the interstitial space, elevating extracellular adenosine levels, which is associated with immunosuppressive effects [93].”

• cites [93] sourceSupported

May combine two claims.

In mouse cancer models, inhibiting HIF-1/2α improves the efficacy of anti-PD1 therapy and increases infiltration of cytotoxic immune effector cells.

“Thus, HIF-1/2α inhibition in mouse models of cancer promotes the efficacy of anti-PD1 therapy and increases infiltration of cytotoxic immune effector cells [84–86].”

• cites [84] sourceNot checked — no full text of the source
• cites [85] sourcePartly supported

  In the Results and discussion (page unavailable), disrupting HIF-1α activity increased NK- and CD8+ T-cell infiltration in mouse melanoma tumors. Acriflavine improved tumor control when added to anti-PD-1 plus a TRP-2 vaccine. The paper does not show that inhibiting HIF-2α has these effects, or establish the anti-PD-1 benefit without the vaccine; HIF-1β, which the paper discusses, is not HIF-2α. (LLM, conf=0.89)

  Experimental — accuracy not yet measured
• cites [86] sourceSupported
  Experimental — accuracy not yet measured

May combine two claims.

Both HIF-1α and HIF-2α activation upregulates the glutamine transporter SLC38A2, increasing glutamine dependency and correlating with worse survival in breast cancer patients.

“Both HIF-1α and HIF-2α activation promotes the upregulation of the glutamine transporter, SLC38A2, which increases the dependency of cells to glutamine and correlates with poorer survival in patients with breast cancer [58]”

• cites [58] sourcePartly supported

  The paper’s main text (indexed under Abstract; page unavailable) reports that hypoxia increases some cells’ dependence on glutamine and discusses HIF involvement in a switch to reductive glutamine metabolism. It does not report HIF-1α or HIF-2α upregulating SLC38A2, or an association with survival in breast cancer patients. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

May combine two claims.

The HIF-α dependency of PD-L1 is tumor-type dependent: PD-L1 expression is primarily HIF-1α driven in HIF-1α-dominant cancers (CT26 colon carcinoma and 4T1 breast carcinoma models) and HIF-2α-driven in HIF-2α-dominant cancers (ccRCC).

“As seen for the other cancer axes, the HIF-α dependency of PD-L1 is tumor-type dependent, with PD-L1 expression primarily HIF-1α driven in HIF-1α-dominant cancers (such as CT26 colon carcinoma and 4T1 breast carcinoma models) and HIF-2α-driven in HIF-2α-dominant cancers (ccRCC) [81, 83].”

• cites [81] sourcePartly supported

  The Results and Discussion (page unavailable) show that HIF-1α, but not HIF-2α, regulates PD-L1 in MSC-1 myeloid-derived suppressor cells. The Methods list CT26 and 4T1 tumor models, but the copy does not establish HIF-1α dependence in those carcinoma cells or compare tumor types; it does not report HIF-2α-driven PD-L1 in ccRCC. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites [83] sourceSupported

May combine two claims.

This chemokine-driven recruitment can suppress anti-tumor immunity and induce chronic inflammation, which promotes cancer progression by facilitating tumor cell proliferation, survival, angiogenesis, and metastasis.

“This can result in suppression of the anti-tumor immune response and induce chronic inflammation, which contributes to cancer progression by facilitating tumor cell proliferation, cell survival, angiogenesis and metastasis [68].”

• cites [68] sourceSupported

May combine two claims.

Lactate enhances cancer-associated fibroblast proliferation and stimulates CAF-mediated IL-6 expression, which suppresses cytotoxic immune cell activity synergistically with lactate.

“Lactate also enhances cancer-associated fibroblast (CAF) proliferation and stimulates CAF-mediated IL-6 expression, which suppresses cytotoxic immune cell activity synergistically with lactate [89].”

• cites [89] sourcePartly supported

  The Introduction and Discussion (page numbers not provided) say that lactate supports CAF growth in the glucose-deprived pancreatic cancer microenvironment. The Results report increased IL-6 production by lactate-stimulated CAFs and reduced cytotoxic-lymphocyte activity when lactate and IL-6 were combined. The claim omits the glucose-deprived pancreatic-cancer setting that bounds the reported CAF growth finding. (LLM, conf=0.83)

  Experimental — accuracy not yet measured

May combine two claims.

Neutralizing antibodies against PD-1/PD-L1 or CTLA4 restore cytotoxic T-cell activity, inducing T-cell-mediated tumor cell destruction, and have transformed cancer treatment.

“Neutralizing antibodies for the PD-1/PD-L1 interaction or for CTLA4 restores the cytotoxic activity of T-cells, which induces T-cell mediated tumor cell destruction, and have transformed the cancer treatment landscape (Table 1) [82].”

• cites [82] sourcePartly supported

  Section 4.3 states that PD-1/PD-L1 blocking antibodies enhance T-cell-mediated antitumor responses and generate cytotoxic T cells capable of killing tumor cells. The Introduction describes checkpoint inhibitors as important to cancer immunotherapy, but the passages on anti-CTLA-4 in Section 8.2 and the Conclusion discuss T-cell infiltration and treatment response, not restoration of cytotoxic activity by anti-CTLA-4 antibodies specifically. The claim's mechanism is therefore supported for PD-1/PD-L1 blockade but not fully for CTLA-4 blockade. (LLM, conf=0.84)

  Experimental — accuracy not yet measured

May combine two claims.

Independent of glycolysis, HIFs induce immunosuppressive metabolites such as adenosine by transcriptionally activating ectoenzymes ENTPD2/CD39L1, CD39, and CD73, which convert extracellular ATP to adenosine, promoting MDSC maintenance and limiting immune checkpoint inhibitor activity.

“Independent of glycolysis, the HIFs can induce the production of immunosuppressive metabolites such as adenosine by transcriptionally activating ectoenzymes such as ENTPD2/CD39L1, CD39, and CD73 (Table 1), which contribute to the multistep conversion of extracellular ATP through ADP/AMP to adenosine, thus promoting the maintenance of MDSCs, which limits the activity of immune checkpoint inhibitors”

• cites [90] sourcePartly supported

  Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  Experimental — accuracy not yet measured
• cites [91] sourcePartly supported

  Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  Experimental — accuracy not yet measured
• cites [92] sourcePartly supported

  Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  Experimental — accuracy not yet measured

May combine two claims.

HIFs promote lipid uptake and lipid droplet formation while decreasing β-oxidation, increasing the cellular fatty acid pool available for energy or other uses that facilitate tumor proliferation.

“In addition to promoting lipid synthesis, the HIFs also directly promote lipid uptake and lipid droplet formation, while decreasing β-oxidation (see section on mitochondria), which increases the cellular fatty acid pool that can be utilized as an energy source or channeled to other uses to facilitate tumor proliferation.”

• cites [57] sourceCould not verify

  The Abstract links hypoxia-related glutamine metabolism to lipid biosynthesis and proliferation, but does not address lipid uptake, lipid droplets, or β-oxidation. Searches for those processes and for a fatty-acid pool found no passage in our copy supporting the attributed claim. (LLM, conf=0.76)

  Experimental — accuracy not yet measured

May combine two claims.

HIF-1α depletion in tumor-infiltrating neutrophils can reverse their pro-tumorigenic phenotype and reduce tumor burden.

“Besides TAMs, HIF-1α is also known to promote the inflammatory response by promoting neutrophil survival, whereas HIF-1α depletion in tumor-infiltrating neutrophils can reverse their pro-tumorigenic phenotype, reducing tumor burden [78, 79].”

• cites [78] sourceSupported
• cites [79] sourceCould not verify

  The Results section reports that HIF-1α-deficient murine bone marrow neutrophils survive less well under anoxic conditions. Our copy does not address tumor-infiltrating neutrophils, reversal of a pro-tumorigenic phenotype, or tumor burden; searches for those terms found no relevant passage. (LLM, conf=0.77)

  Experimental — accuracy not yet measured

May combine two claims.

Targeting glutamine dependency in cancer cells is a promising therapeutic strategy, and many agents against various steps of glutamine metabolism are in development.

“Targeting the glutamine dependency of cancer cells is a promising therapeutic strategy for cancer and many agents targeting various steps of glutamine metabolism are currently in development [63].”

• cites [63] sourceSupported

May combine two claims.

HIF activation in solid tumors causes release of chemokines that recruit immunosuppressive cells such as TAMs, MDSCs, and Tregs, which can limit the anti-tumor activity of Natural Killer and CD8+ T cells.

“HIF activation within solid tumors leads to the release of chemokines that promote the recruitment of immunosuppressive cell types such as tumor-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs), and regulatory T cell (Treg) cells, which can limit the anti-tumor activity of Natural Killer and CD8 + T cells (Figure 1) [67].”

• cites [67] sourcePartly supported

  Section 6.2 (page unavailable) links tumor hypoxia and HIF-1α to MDSC accumulation and Treg activity at the tumor site. Section 2.2 (page unavailable) identifies TAMs, MDSCs, and Tregs as immunosuppressive tumor components and says MDSCs suppress cytotoxic T-cell and NK-cell activity. Neither passage establishes the claimed mechanism of HIF-triggered chemokine release recruiting all three cell types, including TAMs. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

May combine two claims.

TAMs accumulate in hypoxic areas and the tumor microenvironment through HIF-1α activation, which promotes their adaptation to hypoxia.

“For example, TAMs accumulate in hypoxic areas and the TME through HIF-1α activation, promoting TAM adaptation to hypoxia [2, 72].”

• cites [2] sourceSupported
• cites [72] sourcePartly supported

  The Macrophages section (page unavailable) says TAMs accumulate in hypoxic tumor regions, where they upregulate HIF-1α and HIF-2α. It does not say HIF-1α activation causes that accumulation or establishes that it promotes TAM adaptation to hypoxia; the Mini Review section instead links TAM migration in the models discussed to HIF-2α. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

May combine two claims.

ARO-HIF2, an siRNA drug selectively targeting HIF-2α, is under clinical investigation, but Phase I results showed low response rates and off-target neurotoxicity.

“ARO-HIF2, an siRNA drug that selectively targets HIF-2α is also under clinical investigation, but Phase I results showed low response rates and off-target neurotoxicity [109].”

• cites [109] sourceSupported

May combine two claims.

NKT2152 and Casdatifan are HIF-2α inhibitors in clinical trials with promising results, but it remains unclear whether they will provide additional benefit over belzutifan.

“Similarly promising results were obtained with other small molecule inhibitors of HIF-2α currently undergoing clinical trials: NKT2152 (NCT05119335) and Casdatifan (NCT05536141) and it remains unclear whether these new agents will provide additional benefit above that of belzutifan [107, 108].”

• cites [107] sourcePartly supported

  The Abstract (p. S12) identifies NKT2152 as a HIF-2α inhibitor and describes its ongoing Phase 1/2 trial (NCT05119335). It reports promising activity only in preclinical models, not clinical results, and does not address Casdatifan or whether either agent offers additional benefit over belzutifan. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [108] sourcePartly supported

  The Background and Methods (TPS4602, p. 1) identify AB521 as a HIF-2α inhibitor being studied in phase 1 trial NCT05536141, the trial number the citing sentence assigns to Casdatifan. This is a study description, not a report of promising clinical results. It does not address NKT2152 or whether either agent offers additional benefit over belzutifan. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

May combine two claims.

No pharmacological agents specifically targeting HIF-1α have been described, although compounds targeting HIF-1α mRNA expression, protein synthesis/stabilization, and dimerization have been identified.

“Unlike HIF-2α, no pharmacological agents that specifically target HIF-1α have been described, although a number of compounds which target HIF-1α mRNA expression, protein synthesis/stabilization and dimerization, have been identified [110].”

• cites [110] sourcePartly supported

  Section 4.1 describes compounds affecting HIFα mRNA expression, protein synthesis, stability, and heterodimerization, and contrasts them with a selective HIF-2 inhibitor. But the categorical claim that no agent specifically targets HIF-1α overstates the review: section 4.1.1 identifies YC-1 as specifically inhibiting HIF-1, but not HIF-2, expression in macrophages, and section 4.2 describes a peptide that binds HIF-1α but not HIF-2α. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

May combine two claims.

Agents targeting HIFs have typically done so indirectly and non-specifically, including by inhibiting other targets that affect HIF synthesis, stability, or transcriptional activity, or by interfering with cellular iron metabolism, which blocks HIF translation and induces ferroptosis.

“Consequently, agents that target HIFs have typically targeting them indirectly and non-specifically, including by inhibiting other targets that impact HIF synthesis, stability or transcriptional activity [95], or by interfering with cellular iron metabolism, which blocks HIF translation and induces ferroptosis, a form of cell death associated with iron-dependent lipid peroxidation [24].”

• cites [95] sourcePartly supported

  Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  Experimental — accuracy not yet measured
• cites [24] sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Since HIF-1α was discovered in 1991 and HIF-2α in 1997, the importance of the HIF pathway in oxygen sensing was affirmed by the 2019 Nobel Prize and by FDA approval of belzutifan in 2021.

“Since the discovery of HIF-1α in 1991, and of HIF-2α in 1997, the significance of the HIF pathway in oxygen sensing has been affirmed by the awarding of the 2019 Nobel Prize in Physiology and Medicine for the discovery of HIF, followed by the FDA approval of belzutifan in 2021 [111, 112].”

• cites [111] sourcePartly supported

  The “Hypoxia in the patient setting” section says the 2019 Nobel Prize honored research into how cells sense and respond to oxygen, supporting the Nobel Prize portion of the claim. The paper does not give the stated 1991 and 1997 discovery dates or report FDA approval of belzutifan in 2021; it describes HIF-2α inhibitors as investigational. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [112] sourcePartly supported

  The Abstract and Introduction (page not provided) state that the FDA approved belzutifan, a HIF inhibitor, in August 2021. The passages do not give the 1991 and 1997 discovery dates or discuss the 2019 Nobel Prize; those parts of the sentence are not supported by this source. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

May combine two claims.

Tumor hypoxia fluctuates in intensity and duration and includes reoxygenation cycles with oxidative stress that can damage DNA.

“This results in fluctuating intensities and durations of hypoxia combined with cycles of reoxygenation (and associated oxidative stress that can induce DNA damage) that reflect proliferative and vascular variations throughout the tumor mass.”

May combine two claims.

HIF transcription factors are heterodimeric bHLH-PAS proteins with oxygen-labile HIF-α subunits and a constitutive HIF-1β subunit.

“The HIF transcription factors belong to the bHLH-PAS family of heterodimeric transcription factors. They comprise one of three major oxygen labile HIF-α subunits (HIF-1α, HIF-2α, and HIF-3α), and a constitutive HIF-1β subunit (also known as ARNT) [3].”

• cites [3] sourceNot checked — no full text of the source

May combine two claims.

Under oxygen above about 5%, PHDs hydroxylate HIF-α in an iron- and oxygen-dependent manner, leading pVHL polyubiquitination and proteasomal degradation.

“In the presence of oxygen (typically > 5% O2), the HIF-α subunit is hydroxylated by PHDs in an iron and oxygen dependent manner, which leads to HIF-α polyubiquitination by pVHL, targeting HIF-α for proteasomal degradation (Figure 2) [8].”

• cites [8] sourceNot checked — no full text of the source

May combine two claims.

HIFs drive transcriptional changes that alter major cancer signaling axes and promote tumor progression.

“Specifically, the HIFs drive transcriptional changes that drive substantial alterations within major cancer cell signaling axes (the HIF axes) that facilitate tumor progression (Figure 1).”

May combine two claims.

HIF-1α and HIF-2α have largely similar regulation and both overlapping and unique target genes depending on tissue context.

“HIF-1α and HIF-2α show largely similar mechanisms of regulation with both overlapping and unique target genes depending on tissue context [1].”

• cites [1] sourceNot checked — no full text of the source

May combine two claims.

Because HIF activation drives tumor progression and is rarely expressed in normal non-ischemic tissue, targeting HIFs and downstream mediators is an attractive cancer therapy strategy.

“Since HIF activation is a central driver of tumor progression but yet is rarely expressed in normal, non-ischemic tissue, targeting HIFs and their downstream mediators represents an attractive therapeutic strategy for cancer.”

May combine two claims.

Hypoxia-mediated HIF activation normally drives beneficial adaptive responses needed for wound healing, inflammation resolution, and development, but tumor cells exploit this response via hypoxia-dependent or independent HIF activation.

“Although hypoxia-mediated HIF activation typically drives a physiologically beneficial adaptive response to hypoxia, which is required for wound healing, resolution of inflammation, and a variety of developmental processes, this physiological response is exploited by tumor cells through hypoxia-dependent or independent HIF activation [1].”

• cites [1] sourceNot checked — no full text of the source

May combine two claims.

Metabolic rewiring supplies building blocks for nucleic acids, lipids, and proteins to support proliferative tumor cells and is a tightly regulated state, not merely a response to dysfunctional mitochondria as Warburg initially proposed.

“This rewiring of metabolic pathways also supplies building blocks for nucleic acids, lipids and protein synthesis, which supports the increased biosynthetic demand of proliferative tumor cells, and is thus a tightly regulated metabolic state rather than an adaptive response to dysfunctional mitochondria as initially proposed by Warburg.”

May combine two claims.

VEGFA/VEGFR interaction is considered a key regulator of angiogenesis and an important target for anti-angiogenic drugs.

“Despite the plethora of other signaling mediators in the regulation of angiogenesis, the VEGFA/VEGFR interaction is considered a key regulator (Table 1), and an important target for anti-angiogenic drugs.”

• cites Table 1Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

May combine two claims.

Necrosis is associated with increased proliferation and genomic instability in surrounding tissues, which may contribute to tumor progression and patient morbidity.

“Additionally, necrosis is typically associated with increased proliferation and genomic instability in the surrounding tissues, which may also contribute to tumor progression and patient morbidity.”

May combine two claims.

HIF-mediated angiogenesis can promote reperfusion in some tumor regions but can also paradoxically create profound hypoxia and nutrient limitation due to defective vasculature.

“Thus, HIF-mediated angiogenesis, while promoting reperfusion in some tumor regions, can also paradoxically generate regions of profound hypoxia and nutrient limitation due to uneven or defective vasculature.”

May combine two claims.

Uneven tumor blood flow creates chronic or intermittent hypoxia, enhanced permeability, increased interstitial pressure, vessel compression, and poor perfusion that hampers drug delivery.

“This results in uneven blood flow within the tumor, generating regions of chronic or intermittent hypoxia and regions of enhanced permeability and increased interstitial pressure, which can result in compression of tumor vessels and poor vascular perfusion, hampering drug delivery [27].”

• cites [27] sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing).

FDG-PET imaging is widely used in clinical practice for tumor staging, prognosis, and monitoring treatment response.

“PET imaging of 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) uptake is widely used clinically for tumor staging, prognosis and treatment monitoring [52].”

• cites [52] sourceNot checked — no full text of the source

May combine two claims.

The effects of HIFs on mitochondrial metabolism and biogenesis support the hypoxia/HIF-mediated shift to glycolysis while reducing damaging mitochondrial ROS.

“In general, the effects of the HIFs in modulating mitochondrial metabolism and biogenesis further support the hypoxia- and HIF-mediated metabolic shift to glycolysis, while reducing the production of damaging mitochondrial ROS.”

May combine two claims.

Anti-angiogenic agents have shown impressive preclinical activity but are largely ineffective as single agents because their effects are primarily cytostatic.

“However, despite impressive activity in preclinical models, anti-angiogenic agents have proven largely ineffective as single agents due to their primarily cytostatic effects (as opposed to cytotoxic effects).”

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Acetyl-CoA fuels the TCA cycle, generating lipid synthesis intermediates and electron carriers such as NADH for ATP production via the mitochondrial ETC.

“Acetyl-CoA fuels the tricarboxylic acid (TCA) cycle that generates intermediates that drive lipid synthesis, as well as generates electron carriers (eg. NADH) to fuel ATP production through the mitochondrial electron transport chain (ETC) [37].”

• cites [37] sourceNot checked — no full text of the source

May combine two claims.

HIF-1α induces CCL26, which enhances Treg recruitment into ovarian tumors.

“For example, both HIF-1α and HIF-2α induce the production of CCL28, which promotes the recruitment of MDSCs into hepatocellular tumors, whereas HIF-1α induces production of CCL26 that enhances recruitment of Tregs into ovarian tumors (Table 1) [69, 70].”

• cites [69] sourceNot checked — no full text of the source
• cites [70] sourceNot checked — no full text of the source

May combine two claims.

Hypoxia-induced immune modulation in the tumor microenvironment promotes tumor progression by producing cytokines that enhance tumor growth and by recruiting fibroblasts and other stromal cells with tumor-supporting functions.

“Hypoxia-induced immune modulation within the TME influences tumor progression through the production of cytokines that enhance tumor growth, as well as through the recruitment of fibroblasts and other stromal cells that exert tumor-supporting functions [65].”

• cites [65] sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S2 (checkable).

Combining glucose-metabolism-targeting agents with existing therapies may improve cancer treatment outcomes in the future.

“Nevertheless, the combination of these novel agents with existing treatments may provide more effective cancer treatment outcomes in the future.”

May combine two claims.

HIF-1α deficiency reduces macrophage motility and aggregation in the extracellular matrix, suggesting that HIF inhibition could reduce TAM recruitment in cancer.

“Furthermore, HIF-1α deficiency leads to reduced macrophage motility and aggregation in the extracellular matrix, suggesting that HIF inhibition could reduce TAM recruitment in cancer [77].”

• cites [77] sourceNot checked — no full text of the source

May combine two claims.

HIF stabilization promotes the reductive TCA cycle at multiple levels, sustaining the cycle when glucose-derived pyruvate is scarce and supplying intermediates for macromolecular synthesis.

“HIF stabilization promotes the reductive cycle at multiple levels, fueling the TCA cycle in the absence of glucose-derived pyruvate, thus providing key metabolic intermediates required for macromolecular synthesis.”

May combine two claims.

Unlike wound healing that resolves, cancer cells have persistent oncogene-derived stress, including increased cell death and cytokine production, which drive a feed-forward loop of inflammation-induced signaling and immune modulation that promotes tumor progression.

“In contrast to physiological wound-healing responses that resolve after tissue restoration, cancer cells present with persisting oncogene-derived stress, which include increased cell death and cytokine production that contribute to a feed-forward loop of inflammation-induced signaling and immune modulation that contribute to tumor progression.”

• AssumptionRests on an assumption: Cancer cells have persisting oncogene-derived stress that includes increased cell death and cytokine production.

Probably not a substantial claim: may not pass S2 (checkable). May combine two claims.

Improving potency and selectivity of glutamine-metabolism-targeting agents, and combining therapies that hit multiple metabolic pathways, may be needed to realize their full therapeutic potential.

“Future efforts in improving their potency and selectivity, as well as the inclusion of combination therapies targeting multiple metabolic pathways may be required to fully realize their potential as a therapeutic strategy for cancer.”

Probably not a substantial claim: may not pass S3 (load-bearing).

As transcription factors, HIFs were until very recently considered undruggable.

“However, as transcription factors, they were, until very recently, considered undruggable.”

Probably not a substantial claim: may not pass S2 (checkable).

The main challenge ahead is to identify novel, non-redundant targets and/or new combination strategies that can address acquired resistance and improve treatment outcomes.

“While the field continues to advance with the development of improved agents that impact previously validated targets, the challenge ahead lies in the identification of novel, non-redundant targets and/or new combination strategies that can address issues of acquired resistance and improve treatment outcomes (see Outstanding questions).”

May combine two claims.

Acquired resistance from prolonged treatment with HIF-2α inhibitors was observed in a preclinical study, suggesting that resistance is possible with long-term clinical use of belzutifan.

“Acquired resistance from prolonged treatment with HIF-2α inhibitors was also observed in a previous preclinical study suggesting that resistance is possible with long term use of clinical use of belzutifan [105].”

• cites [105] sourceNot checked — no full text of the source

May combine two claims.

Belzutifan showed good tolerability and efficacy in heavily pretreated patients with metastatic renal cell carcinoma, leading to its approval for advanced RCC.

“Belzutifan has also demonstrated good tolerability and efficacy in heavily pretreated patients with metastatic renal cell carcinoma (RCC) (most commonly noted adverse events were anemia, fatigue, dizziness, and hypoxia), which led to its approval for treatment of advanced RCC [98, 99].”

• cites [98]Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

• cites [99] sourceNot checked — no full text of the source

May combine two claims.

The clinical success of belzutifan has transformed the treatment landscape for RCC patients and is likely to advance treatment options for other HIF-2α-driven tumor types.

“The clinical success of belzutifan has transformed the treatment landscape of patients with RCC and is poised to considerably advance treatment options for patients with other HIF-2α-driven tumor types.”

May combine two claims.

Belzutifan, the most advanced HIF-2α inhibitor, showed significant efficacy in VHL disease-related renal cell carcinomas, hemangioblastomas, and pancreatic neuroendocrine tumors, and received FDA approval for VHL-disease-related cancers.

“The most advanced of these inhibitors to date, belzutifan, demonstrated significant efficacy in VHL disease-related renal cell carcinomas, hemangioblastomas, and pancreatic neuroendocrine tumors, and received FDA approval for the treatment of patients with VHL-disease-related cancers [97].”

• cites [97]Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

May combine two claims.

Because HIF-1α and HIF-2α may be redundant and HIF-1α is more widely expressed in solid tumors, selectively inhibiting HIF-1α in HIF-1α-driven tumors or inhibiting both HIF-1α and HIF-2α is likely to further improve patient benefit.

“However, based on the potential redundancy between HIF-1α and HIF-2α, and the more widespread expression of HIF-1α within solid tumors, the selective inhibition of HIF-1α in HIF-1α-driven tumor types or the dual inhibition of both HIF-1α and HIF-2α, are likely to further enhance patient benefit.”

• AssumptionThe authors state this as an assumption: HIF-1α and HIF-2α have redundant functions in tumor progression.
• AssumptionRests on an assumption: HIF-1α is more widely expressed within solid tumors than HIF-2α.

May combine two claims.

HIF-driven adaptation to hypoxia promotes tumor progression by altering three major axes of cancer signaling-angiogenesis, metabolism, and immune modulation-which together play a central role in tumor progression and response to therapy.

“The HIF-driven adaptation to hypoxia facilitates tumor progression by profoundly alterating three major axes of cancer signaling: angiogensis, metabolism and immune modulation that together play a centrol role in tumor progression and response to therapy.”